Skip to main content
Prof. Hartmann interviewed by Dr. Barbara Kreppel for 'Angewandte Nuklearmedizin'

News categories: Publication

Immunology and Nuclear Medicine

Prof. Gunther Hartmann was interviewed for the magazine “Angewandte Nuklearmedizin” and answered questions about immunology and nuclear medicine.

Dr. Barbara Kreppel from the magazine “Angewandte Nuklearmedizin” interviewed Prof. Gunther Hartmann, director of the Institute of Clinical Chemistry and Clinical Pharmacology and founding speaker of the ImmunoSensation2 Cluster of Excellence, on his expertise on immunology and nuclear medicine. 

During the interview, Prof. Gunther Hartmann shed light on emerging trends in the research fields of immune-oncology and autoimmunity, emphasizing the potential of nuclear medicine for the development of diagnostic tools and novel therapies. He gave an interesting perspective on how nuclear medicine advancements could help with cancer therapy and highlighted the importance of nuclear medicine for immune imaging.

The full interview can be found in the latest issue of “Angewandte Nuklearmedizin”.

Interview:

Angewandte Nuklearmedizin 2024; 47: 78–79
DOI 10.1055/a-2183-2133
ISSN 2749-7445
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14,
70469 Stuttgart, Germany

Press contact:

Dr. Barbara Kreppel
Universitätsklinikum Bonn
Klinik und Poliklinik für Nuklearmedizin
Venusberg-Campus 1
53127 Bonn
E-Mail: barbara.kreppel@ukbonn.de

Related news

Kathrin Leppek Publication PM

News categories: Publication

Starting points for the control of protein synthesis

Bonn researchers develop a versatile toolbox for the characterization of IRESes in cells.
View entry
Pandyra Publication Graphical Abstract

News categories: Publication

Genetic mutation affects survival after viral infection

Scientists discovered that haploinsufficiency in the Pax5 gene affects antiviral responses. The study was led by Prof. Dr. Aleksandra Pandyra from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn in collaboration with Prof. Dr. Arndt Borkhardt, Clinic Director at the Pediatric Oncology at the University Hospital Düsseldorf. The findings were published in the latest edition of EMBO Molecular Medicine.
View entry
AG Kürthen Multiple Sclerosis Bonn

News categories: Publication

Potential target for MS therapy discovered

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry

Back to the news overview